Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Atara Biotherapeutics, Inc.
  6. Summary
    ATRA   US0465131078

ATARA BIOTHERAPEUTICS, INC.

(ATRA)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
5.170 USD   -5.31%
04:02pAtara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
01/16Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
01/13Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/30/2023 01/31/2023 02/01/2023 02/02/2023 02/03/2023 Date
4.89(c) 5.07(c) 5.13(c) 5.46(c) 5.17 Last
893 673 895 602 800 486 913 967 783 069 Volume
-7.21% +3.68% +1.18% +6.43% -5.31% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 102 M - -
Net income 2022 -201 M - -
Net cash position 2022 144 M - -
P/E ratio 2022 -2,63x
Yield 2022 19,3%
Sales 2023 35,6 M - -
Net income 2023 -273 M - -
Net cash position 2023 230 M - -
P/E ratio 2023 -2,10x
Yield 2023 19,3%
Capitalization 491 M 491 M -
EV / Sales 2022 3,41x
EV / Sales 2023 7,32x
Nbr of Employees 340
Free-Float 99,4%
More Financials
Company
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. Its platform leverages the biology of EBV T cells and has the capability to... 
Read more
More about the company
Ratings of Atara Biotherapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ATARA BIOTHERAPEUTICS, INC.
04:02pAtara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
01/16Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
01/13Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
01/11Atara Biotherapeutics : JP Morgan Presentation
PU
01/11Transcript : Atara Biotherapeutics, Inc. Presents at 41st Annual J.P. Morgan ..
CI
01/06Atara Biotherapeutics, Inc. : Creation of a Direct Financial Obligation or an Obligation u..
AQ
01/05EF Hutton Initiates Atara Biotherapeutics at Buy With $25 Price Target
MT
01/04Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
BU
2022Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
MT
2022Atara, HealthCare Royalty Sign $31 Million Royalty Interest Financing Deal for Ebvallo
MT
2022Atara Biotherapeutics, Inc. : Entry into a Material Definitive Agreement (form 8-K)
AQ
2022Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with H..
BU
2022Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with H..
CI
2022Atara Biotherapeutics Announces Changes to Its Board of Directors
CI
2022Atara Biotherapeutics' Ebvallo Receives European Commission Approval as First Ever Ther..
AQ
More news
News in other languages on ATARA BIOTHERAPEUTICS, INC.
2022Mise à jour sectorielle : Les actions du secteur de la santé son..
2022Atara et HealthCare Royalty signent un accord de financement de 31 millions de dollars ..
2022Atara Biotherapeutics annonce un accord de financement de 31 millions de dollars sur le..
2022Atara Biotherapeutics annonce des changements au sein de son conseil d'administration
2022Atara Biotherapeutics, Inc. nomme Carol Gallagher à la présidence du conseil d'administ..
More news
Analyst Recommendations on ATARA BIOTHERAPEUTICS, INC.
More recommendations
ETFs positioned on ATARA BIOTHERAPEUTICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Virtus LifeSci Biotech Clinical Trials ETF - USD0.44%4.68%United_States
SPDR S&P Biotech ETF - USD0.31%0.94%United_States
Global X S&P Biotech ETF - AUD0.31%4.44%-United_States
IShares Micro-Cap ETF - USD0.17%4.70%United_States
IShares Nasdaq US Biotechnology - USD0.04%-0.10%United_States
More ETFs positioned on ATARA BIOTHERAPEUTICS, INC.
Chart ATARA BIOTHERAPEUTICS, INC.
Duration : Period :
Atara Biotherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATARA BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 5,17 $
Average target price 18,88 $
Spread / Average Target 265%
EPS Revisions
Managers and Directors
Pascal Touchon President, Chief Executive Officer & Director
Utpal Koppikar Chief Financial Officer & Senior Vice President
Carol Giltner Gallagher Chairman
Manher AJ Joshi Senior Vice President-Global Medical Affairs
Jakob Dupont Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ATARA BIOTHERAPEUTICS, INC.57.62%518
REGENERON PHARMACEUTICALS, INC.4.12%80 230
VERTEX PHARMACEUTICALS5.19%77 978
WUXI APPTEC CO., LTD.15.80%41 417
BIONTECH SE-3.87%35 092
BEIGENE, LTD.15.96%26 559